

Press Releases

All Years

[Advanced Search](#)

JUN 8, 2026

[Perrigo Announces Leadership Transition](#)

MAY 26, 2026

[Perrigo to Present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference](#)

MAY 6, 2026

[Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations](#)

APR 30, 2026

[Perrigo Completes Divestiture of Dermacosmetics Business](#)

APR 29, 2026

[Perrigo Announces Quarterly Dividend](#)

APR 22, 2026

[Perrigo to Release First Quarter 2026 Financial Results on May 6, 2026](#)

MAR 3, 2026

[Perrigo to Present at the UBS Global Consumer and Retail Conference](#)

FEB 26, 2026

[Perrigo Reports Fourth Quarter and Fiscal Year 2025 Financial Results From Continuing Operations](#)

FEB 19, 2026

[Perrigo Announces Quarterly Dividend](#)

FEB 13, 2026

[Perrigo to Release Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026](#)

NOV 18, 2025

[Perrigo to Attend Morgan Stanley Global Consumer & Retail Conference](#)

NOV 5, 2025

[Perrigo Reports Third Quarter 2025 Financial Results From Continuing Operations](#)

NOV 5, 2025

[Perrigo to Conduct Strategic Review of its Infant Formula Business](#)

NOV 4, 2025

[Perrigo to Attend Jefferies Consumer Conference](#)

OCT 29, 2025

[Perrigo Announces Quarterly Dividend](#)

[Perrigo Announces Quarterly Dividend](#)

OCT 22, 2025

[Perrigo to Release Third Quarter 2025 Financial Results on November 5, 2025](#)

AUG 20, 2025

[Perrigo to Attend Barclays 18th Annual Global Consumer Staples Conference](#)

AUG 6, 2025

[Perrigo Reports Second Quarter 2025 Financial Results From Continuing Operations](#)

JUL 30, 2025

[Perrigo Announces Quarterly Dividend](#)

JUL 29, 2025

[Perrigo to Present at the Canaccord Genuity 45th Annual Growth Conference](#)

JUL 23, 2025

[Perrigo to Release Second Quarter 2025 Financial Results on August 6, 2025](#)

JUL 14, 2025

[Perrigo Announces Agreement to Divest Dermacosmetics Business for up to €327 Million](#)

JUL 1, 2025

[Perrigo Announces Strategic Organizational Update to Drive Sustainable Growth and Performance](#)

JUN 4, 2025

[Perrigo Announces Global Operations and Supply Chain Leadership Transition](#)

MAY 23, 2025

[Perrigo to Attend the Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference](#)

MAY 7, 2025

[Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations](#)

APR 30, 2025

[Perrigo Announces Quarterly Dividend](#)

APR 23, 2025

[Perrigo to Release First Quarter 2025 Financial Results on May 7, 2025](#)

FEB 28, 2025

[Perrigo Provides Detailed Plan to Consumerize, Simplify and Scale its Unique Global Self-Care Platform at its Virtual Investor Day](#)

FEB 27, 2025

[Perrigo Reports Fourth Quarter & Fiscal Year 2024 Financial Results From Continuing Operations](#)

FEB 26, 2025

[Perrigo to Attend the UBS 2025 Global Consumer and Retail Conference](#)

FEB 19, 2025

[Perrigo Increases Quarterly Dividend by 5%](#)

JAN 31, 2025

[Perrigo to Release Fourth Quarter and Fiscal Year 2024 Financial Results on February 27, 2025, Host Virtual Investor Day on February 28, 2025](#)

JAN 6, 2025

[Perrigo Expands its Scientific Office; Appoints Abbie Lennox as Executive Vice President and Chief Scientific Officer](#)

NOV 6, 2024

[Perrigo Reports Third Quarter 2024 Financial Results From Continuing Operations](#)

NOV 1, 2024

[Perrigo Announces Quarterly Dividend](#)

OCT 23, 2024

[Perrigo to Release Third Quarter 2024 Financial Results on November 6, 2024](#)

SEP 26, 2024

 **[Perrigo Announces Good Start® and Dr. Browns® Brand Partnership and Launch of Infant Formula Portfolio](#)**

Partnership and Launch of Infant Formula Portfolio

 [Photos](#) (1)

SEP 17, 2024

PERRIGO ANNOUNCES THE CLOSING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY

SEP 12, 2024

PERRIGO ANNOUNCES THE PRICING OF A SENIOR NOTES OFFERING BY ITS FINANCE SUBSIDIARY, PERRIGO FINANCE UNLIMITED COMPANY

SEP 4, 2024

Perrigo Appoints Industry Veteran, Charles Atkinson, as Executive Vice President, General Counsel and Secretary

AUG 27, 2024

Perrigo to Attend the Piper Sandler Growth Frontiers Conference

AUG 19, 2024

Perrigo Appoints David Ball to the Newly Created Position of Executive Vice President and Chief Brand and Digital Officer

AUG 2, 2024

Perrigo Reports Second Quarter 2024 Financial Results From Continuing Operations

AUG 1, 2024

[Perrigo Announces Quarterly Dividend](#)

JUL 31, 2024

[Perrigo to Attend the Canaccord Genuity 44th Annual Growth Conference](#)

JUL 19, 2024

[Perrigo to Release Second Quarter 2024 Financial Results on August 2, 2024](#)

JUL 10, 2024

[Perrigo Completes Divestment of HRA Pharma Rare Diseases Business](#)

MAY 28, 2024

[Perrigo to Attend Oppenheimer 24th Annual Consumer Growth & E-Commerce Conference](#)

MAY 7, 2024

[Perrigo Reports First Quarter 2024 Financial Results From Continuing Operations](#)

MAY 7, 2024

[Perrigo Announces Executive Transition for its Consumer Self-Care International \(CSCI\) Business](#)

MAY 1, 2024

[Perrigo Announces Quarterly Dividend](#)

APR 25, 2024

[Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million](#)

APR 23, 2024

[Perrigo to Release First Quarter 2024 Financial Results on May 7, 2024](#)

MAR 4, 2024

[Perrigo Commences Shipments of Opill® to Retailers Nationwide, Empowering Millions to Enter a New Era of Reproductive Health Access in the United States](#)

 [Video](#) ⁽¹⁾  [Photos](#) ⁽¹⁾

FEB 29, 2024

[Perrigo to Attend UBS Global Consumer and Retail Conference](#)

FEB 27, 2024

[Perrigo Reports Fourth Quarter & Fiscal Year 2023 Financial Results From Continuing Operations; Launches Investment & Efficiency Program](#)

FEB 26, 2024

[Perrigo Increases its Quarterly Dividend](#)

FEB 13, 2024

[Perrigo to Release Fourth Quarter and Fiscal Year 2023 Financial Results on February 27, 2024](#)

NOV 22, 2023

NOV 29, 2023

[**Perrigo Announces Early Results of Cash Tender Offer for Notes**](#)

NOV 10, 2023

[**Perrigo Announces Cash Tender Offer for Notes**](#)

NOV 7, 2023

[**Perrigo Reports Third Quarter Fiscal Year 2023 Financial Results From Continuing Operations**](#)

NOV 2, 2023

[**Perrigo Announces Quarterly Dividend**](#)

OCT 31, 2023

[**Perrigo to Attend Upcoming Consumer Investor Conferences**](#)

OCT 24, 2023

[**Perrigo to Release Third Quarter 2023 Financial Results on November 7, 2023**](#)

SEP 11, 2023

[**Perrigo Announces Leadership Update**](#)

AUG 24, 2023

[**Perrigo to Attend Upcoming Consumer Investor Conferences**](#)

AUG 8, 2023

[**Perrigo Reports Second Quarter Fiscal Year 2023 Financial Results From Continuing Operations**](#)

AUG 2, 2023

[PERRIGO ANNOUNCES QUARTERLY DIVIDEND](#)

JUL 25, 2023

[Perrigo to Release Second Quarter 2023 Financial Results and Present at an Industry Growth Conference](#)



JUL 13, 2023

[Perrigo Announces U.S. FDA Approval for Opill® OTC Daily Oral Contraceptive](#)

 [Photos \(1\)](#)

JUN 8, 2023

[Perrigo Appoints Patrick Lockwood-Taylor as President and CEO](#)

MAY 24, 2023

[Perrigo to Host 1x1 Investor Meetings at the 23rd Annual Oppenheimer Consumer Growth & E-Commerce Conference](#)

MAY 16, 2023

[PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR NICOTINE COATED MINT LOZENGE](#)

MAY 10, 2023

[FDA Joint Advisory Committee Votes in Favor of Perrigo's Opill® Daily Oral Contraceptive for OTC Use](#)

MAY 9, 2023

[Perrigo Reports First Quarter Fiscal Year 2023 Financial Results From Continuing Operations](#)

MAY 9, 2023

[Perrigo Announces Chief Executive Officer Retirement and Succession Plan](#)

MAY 4, 2023

[PERRIGO ANNOUNCES QUARTERLY DIVIDEND](#)

APR 25, 2023

[Perrigo to Release First Quarter 2023 Financial Results on May 9, 2023](#)

MAR 28, 2023

[Perrigo Announces New Date for Joint FDA Advisory Committee Meeting to Review Opill® Daily Oral Contraceptive for OTC Use](#)



MAR 17, 2023

[Perrigo Announces Voluntary Recall of Limited Quantity of Gerber® Good Start® SoothePro™ Powdered Infant Formula](#)

 [Photos \(1\)](#)

MAR 2, 2023

[Perrigo to Present at Upcoming 12th Annual UBS Global Consumer and Retail Conference](#)



MAR 1, 2023

[Perrigo Announces FDA Approval of the Store Brand OTC Equivalent of Advil® Dual Action Tablets](#)

 [Photos \(1\)](#)

FEB 28, 2023

[Perrigo Launches its 3-Year Optimize and Accelerate Strategic Plan, Issues Fiscal 2023 Guidance and Introduces 2025 Financial Targets at Investor Day](#)

FEB 27, 2023

[Perrigo Reports Fourth Quarter & Fiscal Year 2022 Financial Results From Continuing Operations](#)

FEB 21, 2023

[Perrigo Increases its Quarterly Dividend](#)

FEB 14, 2023

[Perrigo to Release Fourth Quarter and Fiscal Year 2022 Financial Results on February 27, 2023, Conduct Virtual Investor Day on February 28, 2023](#)

DEC 19, 2022

[Perrigo to Host Virtual Investor Day on February 28, 2023](#)

NOV 8, 2022

[Perrigo Reports Third Quarter Fiscal Year 2022 Financial Results From Continuing Operations](#)

NOV 3, 2022

[Perrigo Announces Quarterly Dividend](#)



NOV 1, 2022

[Perrigo Announces Strategic Investment to Expand and Strengthen U.S. Manufacturing of Infant Formula](#)

 [Photos](#) (1)

OCT 26, 2022

[Perrigo Receives Notification of Postponement for Joint FDA Advisory Committee to Review Opill® Daily Oral Contraceptive for Over-The-Counter \(OTC\) Use](#)

OCT 25, 2022

[Perrigo to Release Third Quarter 2022 Financial Results on November 8, 2022](#)

SEP 12, 2022

[PERRIGO ANNOUNCES JOINT FDA ADVISORY COMMITTEE TO REVIEW OPILL® DAILY ORAL CONTRACEPTIVE FOR OVER-THE-COUNTER \(OTC\) USE](#)

AUG 17, 2022

[PERRIGO RELEASES STATEMENT ON RECENT MARKET TRADING ACTIVITY](#)

AUG 9, 2022

[PERRIGO REPORTS SECOND QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS](#)

AUG 2, 2022

[PERRIGO ANNOUNCES QUARTERLY DIVIDEND](#)

JUL 27, 2022

[PERRIGO TO RELEASE SECOND QUARTER 2022 FINANCIAL RESULTS ON AUGUST 9, 2022](#)

JUL 11, 2022

[Perrigo's HRA Pharma Submits Application to FDA for First-Ever OTC Birth Control Pill](#)

JUN 1, 2022

[PERRIGO PROMOTES ALISON IVES TO ROLE OF CHIEF SCIENTIFIC OFFICER](#)

Show per page

« 1 2 3 4 5 6 7 8 9 10 »



<https://investor.perrigo.com/press-releases?l=100&searchform=1>